Hadi Berry, DO
Internal Medicine · Detroit, MINPI 1316067895
Payments from drug & device makers
Across 133 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$385
- Novo Nordisk$383
- Amgen$282
- Lilly USA, LLC$257
- GSK$244
- Boehringer Ingelheim$228
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,982100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $385 |
| Novo Nordisk | 20 | $383 |
| Amgen | 12 | $282 |
| Lilly USA, LLC | 17 | $257 |
| GSK | 15 | $244 |
| Boehringer Ingelheim | 12 | $228 |
| Pfizer | 14 | $223 |
| Amarin Pharma, Inc. | 2 | $138 |
| Regeneron Healthcare Solutions, Inc. | 1 | $130 |
| Axsome Therapeutics, Inc. | 1 | $111 |
| AstraZeneca | 6 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $97 |
| Novartis | 5 | $70 |
| AbbVie | 3 | $62 |
| Indivior Inc. | 2 | $34 |
| Alkermes, Inc. | 1 | $28 |
| Dexcom, Inc. | 1 | $24 |
| Akcea Therapeutics, Inc. | 1 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Merz North America, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Bioventus LLC | 1 | $18 |
| Verona Pharma, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Orexo US, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,982 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $141,097 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 132 | $96,180 |
| JardianceEmpagliflozin | 130 | $94,906 |
| EliquisApixaban | 69 | $54,046 |
| JanuviaSitagliptin Phosphate | 47 | $39,217 |
| VivitrolNaltrexone Microspheres | 22 | $36,202 |
| LinzessLinaclotide | 54 | $30,165 |
| FarxigaDapagliflozin Propanediol | 29 | $28,956 |
| TrulicityDulaglutide | 25 | $25,181 |
| RybelsusSemaglutide | 16 | $19,460 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $14,570 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $14,138 |
| Spiriva HandihalerTiotropium Bromide | 16 | $12,323 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $12,266 |
| EntrestoSacubitril/Valsartan | 16 | $10,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $383 | $160,557140 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $244 | $122,583182 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $228 | $107,097154 claims |
| PfizerEliquis | $223 | $54,04669 claims |
| Alkermes, Inc.Vivitrol | $28 | $36,20222 claims |
| AstraZenecaFarxiga, Symbicort | $101 | $35,70360 claims |
| AbbVieLinzess | $62 | $30,16554 claims |
| Lilly USA, LLCTrulicity | $257 | $25,18125 claims |
| NovartisEntresto | $70 | $10,61816 claims |
| Indivior Inc.Suboxone | $34 | $7,59114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Detroit
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Rana BalboulDetroit$2.4M
- Philip KuriakoseDetroit$1.9M
- Erlene SeymourDetroit$797K
- Sheela TejwaniDetroit$712K
- Vrushali DabakDetroit$509K
- James McCordDetroit$493K
- Saroj NeupaneDetroit$487K
- David StocktonDetroit$402K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.